Titre :

Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.

Auteur(s) :

Waszczuk-Gajda, Anna [Auteur]
Medical University of Warsaw - Poland
Gras, Luuk [Auteur]
De Wreede, Liesbeth C. [Auteur]
Leiden University Medical Center [LUMC]
Sirait, Tiarlan [Auteur]
Illes, Arpad [Auteur]
University of Debrecen
Ozkurt, Zubeyde Nur [Auteur]
Gazi University
Snowden, John A. [Auteur]
Sheffield Children's NHS Foundation Trust
Arat, Mutlu [Auteur]
Bulabois, Claude Eric [Auteur]
Université Grenoble Alpes [UGA]
Niederland, Judith [Auteur]
Helios Klinikum [Erfurt]
Sever, Matjaz [Auteur]
University Medical Centre Ljubljana [Ljubljana, Slovenia] [UMCL]
Paneesha, Shankara [Auteur]
University Hospitals Birmingham [Birmingham, Royaume-Uni]
Potter, Victoria [Auteur]
King's College Hospital [KCH]
Gadisseur, Alain [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Chalopin, Thomas [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Van Gorkom, Gwendolyn [Auteur]
School for Oncology and Developmental Biology [Maastricht] [GROW]
López, Joaquin Martinez [Auteur]
Hospital Universitario 12 de Octubre [Madrid]
Kerre, Tessa [Auteur]
Universiteit Gent = Ghent University = Université de Gand [UGENT]
Drozd-Sokolowska, Joanna [Auteur]
Medical University of Warsaw - Poland
Raj, Kavita [Auteur]
King's College Hospital [KCH]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Schonland, Stefan O. [Auteur]
Heidelberg University Hospital [Heidelberg]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Date de publication :

2023-01-23

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on ...
Lire la suite >The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Sixty-three (57%) patients had light chain MM. All patients required dialysis (94% hemodialysis and 6% peritoneal). Forty-four of 71 (62%) patients received bortezomib-based induction regimens and 42 (39%) patients had achieved at least a very good partial response (VGPR) pre-ASCT. Melphalan dosing was as follows: ≤140 mg/m2 (82%), and >140 mg/m2 (18%). The median PFS after ASCT was 35 months (95% CI: 21.5–42.2) and the median OS 102 months (95% CI: 70.4–129.1). At 1, 2, and 5 years after ASCT, 8% (95% CI 3–14%), 13% (6–20%), and 20% (12–29%) of patients, respectively, had achieved dialysis independence. In multivariate analyses of OS and PFS including age at ASCT, response at ASCT, and year of ASCT, younger age at ASCT and better response at ASCT (CR/VGPR/PR vs. MR/SD/progression) were significantly associated with better OS and PFS.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T23:36:20Z
2024-03-05T10:22:13Z